Purchase this article with an account.
Naziha Slimani, Mercy D Pawar, Zeynep Gursel Ozkurt, Ronald Tucker, Prem Vaishnava, Cagri G Besirli, Hakan Demirci; Magnetic Hyperthermia Treatment in Y-79 Retinoblastoma and ARPE-19 RPE Cells: Concentration Dependent Effect of Iron Oxide Nanoparticle. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3995.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the selective death of Y-79 retinoblastoma cells by using different concentrations of dextran-coated iron oxide nanoparticles in magnetic hyperthermia therapy.
Y-79 retinoblastoma and ARPE-19 control cells were incubated with dextran-coated iron oxide nanoparticles solution at 500 μg/ml, 750 μg/ml and 1000 μg/ml. The cells were then subjected to magnetic field for 20 minutes at 45 to 46 degrees Celcius. The temperature was measured using a fiber optic thermometer. Cell Viability analysis was done using CellTiter-Glo Luminescent Assay after 4 hr and 24 hr of treatment. cells without nanoparticles and with nanoparticles not subjected to magnetic hyperthermia treatment were used as controls. The pH of nenoparticles solutions was also recorded
No cytotoxicity-associated death due to pH of the nanoparticles solution was observed. Following magnetic hyperthermia therapy by using iron oxide nanoparticles at the concentration 750μg/ml, cell viability of Y-79 cells was of 94% at 4 hr and 38% at 24 hr.Viability for Y-79 cells was 99.5% and 60% at 4 and 24 hours respectively fo 500 μg/ml nanoparticle solution. No significant cell death was measured in ARPE-19 control group with either concentration of nanoparticle solution. Magnetic hyperthermia treatment in the absence of iron oxide nanoparticles did not induce cell death. Non-specific cytotoxicity of iron oxide nanoparticle solution was seen at 24 hours in cells exposed to 1000 μg/ml concentration.
Our results demonstrate that magnetic hyperthermia using iron oxide nanoparticles lead to selective death in retinoblastoma cells.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.
This PDF is available to Subscribers Only